Each business day, TheStreet.com Ratings compiles a list of the top five stocks in one of five categories -- fast-growth, all-around value, large-cap, mid-cap and small-cap -- based on data from the close of the previous trading session. Today, large-cap stocks are in the spotlight.These are stocks of companies with market capitalizations of over $10 billion that rank near the top of all stocks rated by our proprietary quantitative model, which looks at more than 62 factors. In addition, the stocks must be followed by at least one financial analyst who posts estimates on the Institutional Brokers' Estimate System. The stocks are ordered by their potential to appreciate. Note that no provision is made for off-balance-sheet assets such as unrealized appreciation/depreciation of investments, market value of real estate or contingent liabilities that might affect book value. This could be material for some companies with large underfunded pension plans. Amgen ( AMGN) is a global biotech company that focuses its research and development efforts on new drug therapies in the form of proteins, monoclonal antibodies and small molecules. We upgraded our rating on Amgen shares to a buy in August based on the company's solid stock price performance, impressive record of earnings and revenue growth as well as notable return on equity. For the third quarter, the company reported that its revenue grew 7.3% year over year. While this growth was less than the industry average of 17.2%, it does appear to have helped boost earnings per share, which rose from 18 cents a year ago to $1.09 in the most recent quarter. The increase in EPS represents the continuation of a trend of positive earnings growth over the past year, a trend we feel should continue.